Cellyan Biotechnology (HKPD) Total Non-Current Liabilities (2024 - 2026)
Cellyan Biotechnology (HKPD) posted quarterly Total Non-Current Liabilities of $1.5 million for Q3 2025, up 21.38% year-over-year from $1.2 million in Q3 2024, and down 3.04% quarter-over-quarter from $1.5 million in Q1 2025.
Cellyan Biotechnology (HKPD) Total Non-Current Liabilities (2024 - 2026) Analysis & Trends
Cellyan Biotechnology (HKPD) has reported Total Non-Current Liabilities for 2 consecutive years, with $1.5 million the latest figure, recorded in Q3 2025.
- In Q3 2025, Total Non-Current Liabilities rose 21.38% year-over-year to $1.5 million; the TTM figure through Sep 2025 stood at $1.5 million (up 21.38% YoY), while the FY2025 annual figure was $1.5 million, up 22.08% from the prior year.
- Total Non-Current Liabilities fell to $1.5 million in Q3 2025 per HKPD's latest filing, from $1.5 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $1.5 million in Q1 2025 and bottomed at $1.2 million in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Mckesson | 102.57 Bn | 97.41 Bn | 3.69 Bn | 83.27 Bn |
| 2 | Cencora | 61.35 Bn | 58.53 Bn | 3.61 Bn | -2.92 Bn |
| 3 | Cardinal Health | 54.15 Bn | 49.30 Bn | 2.56 Bn | - |
| 4 | Henry Schein | 10.05 Bn | 9.89 Bn | 1.10 Bn | 6.22 Bn |
| 5 | Akso Health | 671.90 Mn | 671.70 Mn | - | 2,565.00 |
| 6 | Edap Tms | 154.62 Mn | 133.07 Mn | 7.34 Mn | 75.80 Mn |
| 7 | Accendra Health | 90.69 Mn | 83.04 Mn | 263.41 Mn | 2.45 Bn |
| 8 | 111 | 31.31 Mn | -27.44 Mn | 18.18 Mn | 251.86 Mn |
| 9 | Cosmos Health | 13.28 Mn | 10.84 Mn | 1.51 Mn | 38.31 Mn |
| 10 | Cellyan Biotechnology | 6.70 Mn | 6.48 Mn | - | 65,275.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 65,275.00 |
| Sep 30, 2025 | 1.46 Mn |
| Mar 31, 2025 | 1.51 Mn |
| Sep 30, 2024 | 1.21 Mn |
| Mar 31, 2024 | 1.24 Mn |